Dr. Shaomei Feng has extensive clinical experience in the diagnosis and management of lymphoma and other malignant hematologic diseases. She has a strong professional foundation and considerable expertise in handling complex and high-risk cases. Her work focuses on the precision diagnosis and comprehensive treatment of relapsed and refractory lymphoma, and she has accumulated substantial hands-on experience in CAR-T cell therapy, autologous hematopoietic stem cell transplantation, and clinical trial management of novel therapeutics.
Dr. Feng is also deeply engaged in the development of innovative treatment strategies and clinical research. She has participated in multiple clinical studies involving CAR-T cell therapies and emerging drugs, contributing to the advancement of new therapeutic approaches and their real-world clinical application. Her team’s research findings have been presented at major international hematology conferences, including ASH, EHA, and EBMT, reflecting her continued academic contributions and professional impact in the field.
